Last reviewed · How we verify

ABX464 — Competitive Intelligence Brief

ABX464 (ABX464) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA splicing modulator. Area: Immunology, Infectious Disease.

phase 3 RNA splicing modulator RNA splicing machinery (non-specific modulator) Immunology, Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ABX464 (ABX464) — Abivax S.A.. ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABX464 TARGET ABX464 Abivax S.A. phase 3 RNA splicing modulator RNA splicing machinery (non-specific modulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA splicing modulator class)

  1. Abivax S.A. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABX464 — Competitive Intelligence Brief. https://druglandscape.com/ci/abx464. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: